Mylan 4Q Revenues: $2.1 billion (+18%) 4Q Earnings: $190.5 million (+5%) FY Revenues: $7.7 billion (+13%) FY Earnings: $933.1 million (+49%) Comments: Generics segment sales were $1.8 billion in the quarter, up 16%, with North American sales of $1.0 billion, up 17%; European sales of $373.4 million, down 1%; and Rest of World sales were $441.0 million, up 13%. Specialty segment sales were $242.7 million, up 38% driven by EpiPen Auto-Injector sales with increased volume and favorable pricing...